Blood & Organ Banks in European Union: Market Size, Businesses & Forecast 2026

The Blood and Organ Banks industry in the European Union comprises establishments dedicated to the collection, testing, processing, storage, and distribution of human blood, blood components, tissues, and cells, alongside the procurement and allocation of transplantable organs. The sector is transitioning away from decades-old frameworks toward a highly harmonized governance model to protect donor health, secure supplies, and facilitate cross-border safety networks. For instance, according to the European Commission, public and non-profit national networks reported a total of 31 European countries actively reporting critical monitoring data via unified frameworks such as the annual SARE repo

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Blood & Organ Banks in European Union industry cover?

This industry encompasses specialized, mostly public or non-profit entities tasked with managing substances of human origin (SoHO) intended for clinical application. Its activities include blood donor recruitment, whole blood and plasma collection, processing into components (like red blood cells and plasma-derived medicinal products), and the logistics of organ procurement for transplantation. The regulatory definitions are shifting to treat blood, tissues, cells, and organs under a unified framework prioritizing safety, traceability, and ethical non-commercialization.

• •Covers blood donor stations, blood processing laboratories, cord blood banks, bone marrow registries, and regional organ procurement organizations.
• •Focuses on maintaining the structural chain of custody from human donors to clinical recipients across all 27 EU member states.
• •Includes the fractionation support systems that channel recovered plasma into essential therapeutic proteins and immunoglobulins.

Who operates in the industry and how is it structured?

The European market operates primarily as a public service or non-profit state-designated monopoly model to prevent commercial exploitation of human biological materials. Blood establishments are typically public agencies, Red Cross societies, or hospital-integrated banks, while organ distribution is coordinated by specialized international and national bodies. Private operators exist selectively, focusing primarily on commercial plasma collection and private cord blood or tissue cryopreservation services.

• •National networks like Sanquin in the Netherlands and the Etablissement Français du Sang (EFS) in France serve as centralized countrywide operators.
• •Organ allocation is managed through highly coordinated public foundations such as Eurotransplant (covering Germany, Austria, Benelux, Croatia, Hungary, and Slovenia) and Scandiatransplant in the Nordic region.
• •Commercial participation is concentrated in plasmapheresis centers operated by multinational fractionators to supply pharmaceutical lines.

What drives demand in the industry?

Demand in the sector is directly driven by the medical requirements of an aging European demographic, requiring continuous surgical procedures, cancer therapies, and chronic disease management. Structural shortages in plasma collection have heightened the focus on European self-sufficiency to reduce dependence on third-country imports for plasma-derived medicinal products (PDMPs). Furthermore, advancements in complex transplant surgeries and cell-based therapies continue to put pressure on donor acquisition and storage infrastructure.

• •An aging population accelerates the demand for surgical blood components, cardiovascular procedures, and oncological treatments.
• •The growing global and regional clinical requirement for immunoglobulins and clotting factors drives intensive plasma collection initiatives.
• •Emergency preparedness mandates oblige member states to maintain strategic minimum national stockpiles for clinical crises.

Who are the notable companies in the industry?

True 'competition' in the traditional corporate sense is limited due to the non-profit, state-subsidized mandate of blood and organ procurement in Europe. However, large multinational biopharmaceutical and healthcare enterprises interact heavily with this ecosystem by managing authorized plasma collection grids or supplying the testing, processing, and hardware infrastructure used by public banks. These operators face strict oversight concerning donor compensation and product purity.

• •Grifols, S.A. operates a substantial network of plasma donor centers and fractionation infrastructure within Europe and globally.
• •Eurofins Scientific SE provides extensive specialized clinical testing, donor screening, and safety validation assays to European blood and tissue banks.
• •Sanquin acts as a major non-profit operator managing the complete clean-blood supply chain and manufacturing activities in the Netherlands.
• •Etablissement Français du Sang (EFS) stands as the unique public monopoly operator managing blood transfusions and donor networks across France.

What are the recent trends and outlook?

The primary trend shaping the industry's direction is the ongoing digital and operational preparation for a modern legislative architecture across the EU. Systems are increasingly relying on centralized data tools to track critical indicators, monitor adverse reactions, and optimize supply-demand imbalances across borders. Efforts are expanding to enhance donor recruitment strategies among younger demographics through digital engagement and flexible collection setups.

• •The implementation of the European Commission's Big Data Test Infrastructure (BDTI) allows the European Blood Alliance (EBA) to securely aggregate clinical data.
• •Enhanced supply chain monitoring focuses heavily on 'financial neutrality' rules to ensure donors receive reimbursement without commercial profit.
• •Advanced automation in blood screening laboratories is rising to lower processing turnaround times and detect emerging infectious paths.

How is the industry regulated?

The European industry is undergoing its most profound regulatory overhaul in two decades, migrating to a centralized standard of safety and quality control. Regulation (EU) 2024/1938 on standards of quality and safety for substances of human origin (SoHO Regulation), published in July 2024, is set to fully apply in 2027. This framework repeals older individual directives to establish a unified, future-proof oversight system covering blood, tissues, cells, and donor therapies under one roof.

• •Regulation (EU) 2024/1938 replaces the historical Directives 2002/98/EC (Blood) and 2004/23/EC (Tissues and Cells) to create a harmonized EU framework.
• •The newly established SoHO Coordination Board (SCB) serves as a core advisory body to support Member States with consistent compliance enforcement.
• •National Competent Authorities (NCAs) are required to compile and submit comprehensive Serious Adverse Reactions and Events (SARE) data annually to the European Commission.

Government, statistical and trade sources used for this Claight analysis.

• European Union Regulation (EU) 2024/1938 (SoHO Regulation) ·
• European Commission Annual SARE Report 2024 Tissues & Cells ·
• Council of Europe / European Directorate for the Quality of Medicines & Healthcare (EDQM) Blood Conference 2025 Reports ·
• European Blood Alliance (EBA) Annual Communications